Key result
A machine learning model combining clinical baseline variables and blood-derived molecular data accurately predicted 5-year progression to diabetic kidney disease with an AUROC of 0.99.
Why the study?
The study aimed to apply machine learning algorithms to predict future progression to diabetes complications, including diabetic kidney disease and diabetic retinopathy, in type 1 diabetes.
Does the addition of blood-derived metabolomics and lipidomics data to clinical risk factors improve the prediction of microvascular complications in adults with type 1 diabetes?
Cohort (n=385)
No
Does the addition of blood-derived metabolomics and lipidomics data to clinical risk factors improve the prediction of microvascular complications in adults with type 1 diabetes?
The addition of blood-derived metabolomics and lipidomics to traditional clinical risk factors significantly improves the accuracy of machine learning models in predicting the 5-year progression of diabetic kidney disease and retinopathy in patients with type 1 diabetes.
Answers are grounded in this paper and cite their sources.
May refine DKD prediction in type 1 diabetes; leaves open prospective validation before clinical use.
OBJECTIVE: Our aim was to apply state-of-the-art machine learning algorithms to predict the risk of future progression to diabetes complications, including diabetic kidney disease (≥30% decline in eGFR) and diabetic retinopathy (mild, moderate or severe). RESEARCH DESIGN AND METHODS: Using data in a cohort of 537 adults with type 1 diabetes we predicted diabetes complications emerging during a median follow-up of 5.4 years. Prediction models were computed first with clinical risk factors at baseline (17 measures) and then with clinical risk factors and blood-derived metabolomics and lipidomics data (965 molecular features) at baseline. Participants were first classified into two groups: type 1 diabetes stable (n=195) or type 1 diabetes with progression to diabetes complications (n=190). Furthermore, progression of diabetic kidney disease (≥30% decline in eGFR; n=79) and diabetic retinopathy (mild, moderate or severe; n=111) were predicted in two complication-specific models. Models were compared by 5-fold cross-validated area under the receiver operating characteristic (AUROC) curves. The Shapley additive explanations algorithm was used for feature selection and for interpreting the models. Accuracy, precision, recall, and F-score were used to evaluate clinical utility. RESULTS: During a median follow-up of 5.4 years, 79 (21 %) of the participants (mean+-SD: age 54.8 +- 13.7 years) progressed in diabetic kidney disease and 111 (29 %) of the participants progressed to diabetic retinopathy. The predictive models for diabetic kidney disease progression were highly accurate with clinical risk factors: the accuracy of 0.95 and AUROC of 0.92 (95% CI 0.857;0.995) was achieved, further improved to the accuracy of 0.98 and AUROC of 0.99 (95% CI 0.876;0.997) when omics-based predictors were included. The predictive panel composition was: albuminuria, retinopathy, estimated glomerular filtration rate, hemoglobin A1c, and six metabolites (five identified as ribitol, ribonic acid, myo-inositol, 2,4- and 3,4-dihydroxybutanoic acids). Models for diabetic retinopathy progression were less predictive with clinical risk predictors at, AUROC of 0.81 (95% CI 0.754;0.958) and with omics included at AUROC of 0.87 (95% CI 0.781;0.996) curve. The final retinopathy-panel included: hemoglobin A1c, albuminuria, mild degree of retinopathy, and seven metabolites, including one ceramide and the 3,4-dihydroxybutanoic acid). CONCLUSIONS: Here we demonstrate the application of machine learning to effectively predict five-year progression of complications, in particular diabetic kidney disease, using a panel of known clinical risk factors in combination with blood small molecules. Further replication of this machine learning tool in a real-world context or a clinical trial will facilitate its implementation in the clinic.
No takes yet. Share an insight, caveat, or question.
Al‐Sari et al. (2021) conducted a cohort in Type 1 Diabetes (n=385). Machine learning model combining clinical and omics data vs. Clinical variables alone was evaluated on Progression to diabetic kidney disease (≥30% decline in eGFR) (AUROC 0.99, 95% CI 0.876-0.997). A machine learning model combining clinical baseline variables and blood-derived molecular data accurately predicted 5-year progression to diabetic kidney disease with an AUROC of 0.99.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: